Viemed Healthcare, Inc. $VMD Shares Bought by Arrowstreet Capital Limited Partnership

Key Points

• Arrowstreet Capital more than doubled its Viemed Healthcare position in the first quarter, adding 358,863 shares to own 711,186 shares, or 1.85% of the company valued at approximately $6.55 million.
• Institutional investors and hedge funds collectively own 74.24% of Viemed’s outstanding shares, while several other firms, including Invesco and Martingale Asset Management, also increased their holdings.
• Viemed reported quarterly revenue of $75.41 million, exceeding estimates, but its $0.06 EPS missed expectations of $0.09. Analysts maintain a consensus “Hold” rating, with the stock recently trading at $11.67.

Arrowstreet Capital Limited Partnership lifted its position in shares of Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) by 101.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 711,186 shares of the company's stock after acquiring an additional 358,863 shares during the period. Arrowstreet Capital Limited Partnership owned 1.85% of Viemed Healthcare worth $6,550,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of Viemed Healthcare by 2.2% in the first quarter. Bank of New York Mellon Corp now owns 81,326 shares of the company's stock valued at $749,000 after purchasing an additional 1,773 shares during the period. Martingale Asset Management L P boosted its position in shares of Viemed Healthcare by 6.0% during the fourth quarter. Martingale Asset Management L P now owns 42,483 shares of the company's stock worth $316,000 after buying an additional 2,399 shares during the period. Invesco Ltd. boosted its position in shares of Viemed Healthcare by 17.1% during the fourth quarter. Invesco Ltd. now owns 21,773 shares of the company's stock worth $162,000 after buying an additional 3,173 shares during the period. State of Alaska Department of Revenue bought a new position in Viemed Healthcare in the 4th quarter worth approximately $25,000. Finally, Barclays PLC grew its holdings in Viemed Healthcare by 2.7% in the 4th quarter. Barclays PLC now owns 131,759 shares of the company's stock worth $979,000 after buying an additional 3,480 shares in the last quarter. Institutional investors and hedge funds own 74.24% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Viemed Healthcare in a research note on Friday, July 17th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Hold".

Viemed Healthcare Price Performance

Shares of NASDAQ:VMD opened at $11.67 on Monday. Viemed Healthcare, Inc. has a 12 month low of $5.93 and a 12 month high of $12.61. The stock has a market cap of $447.43 million, a price-to-earnings ratio of 31.54 and a beta of 1.10. The stock's 50 day moving average price is $11.12 and its 200 day moving average price is $9.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.22 and a quick ratio of 1.10.

Viemed Healthcare (NASDAQ:VMD - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.03). Viemed Healthcare had a net margin of 5.20% and a return on equity of 10.52%. The firm had revenue of $75.41 million for the quarter, compared to the consensus estimate of $74.40 million. Equities research analysts anticipate that Viemed Healthcare, Inc. will post 0.44 earnings per share for the current fiscal year.

Insider Activity at Viemed Healthcare

In related news, insider William Frazier sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $11.72, for a total transaction of $117,200.00. Following the completion of the sale, the insider directly owned 73,214 shares in the company, valued at approximately $858,068.08. This trade represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Timothy Smokoff sold 20,000 shares of the company's stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total transaction of $230,000.00. Following the completion of the transaction, the director owned 75,518 shares in the company, valued at approximately $868,457. This represents a 20.94% decrease in their position. The disclosure for this sale is available in the SEC filing. 20.60% of the stock is currently owned by corporate insiders.

About Viemed Healthcare

Viemed Healthcare, Inc NASDAQ: VMD is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.